Skip to main content
PLOS One logoLink to PLOS One
. 2025 Mar 18;20(3):e0317000. doi: 10.1371/journal.pone.0317000

Evaluation of community pharmacists’ knowledge and attitude about Hajj and Umrah-related health conditions in the western region, Saudi Arabia: A cross-sectional study

Nasser M Alorfi 1,*, Ahmed M Ashour 1, Maan H Harbi 1, Fahad S Alshehri 1
Editor: Mohamed R Abonazel2
PMCID: PMC11918331  PMID: 40100885

Abstract

Background

During the Hajj and Umrah seasons in Saudi Arabia, pilgrims tend to experience a higher frequency of various health conditions. Respiratory infections, gastrointestinal infections, and food poisoning are among the most prevalent ailments. To address these health concerns, community pharmacists (CPs) have developed standardized treatment protocols. Pharmacists’ skills in medication dispensing, health consultations, and preventive care enhance pilgrims’ well-being in challenging pilgrimage settings.

Aims

The objective of this study was to investigate the knowledge and attitude of CPs towards health conditions related to Hajj and Umrah in the Western Region of Saudi Arabia where the Hajj and Umrah are taking place.

Methods

Between March and April 2023, an online cross-sectional study using Google form was carried out among CPs who work in the western region of Saudi Arabia. The study made use of a self-administered questionnaire consisting of four sections that aimed to obtain information about the CPs’ knowledge and attitudes towards health conditions related to Hajj and Umrah. Data analysis was conducted using the Statistical Package for the Social Sciences version 26 (SPSS).

Result

A total of 496 CPs completed and returned the questionnaire, by giving a response rate of 99.2% (n = 500). Among them, 55.1% were aware of the necessary vaccines for Hajj and Umrah. Approximately 46.6% of CPs provided health-related advice to pilgrims. The most common health conditions experienced by pilgrims were diarrhea (59.5%), followed by flu and cough (58%), gastrointestinal diseases (39.4%), food poisoning (33.6%), viral fever, and heat stroke (24.4%). Regarding attitudes towards vaccination, 55.3% of CPs agreed that vaccination is safe for pilgrims aged 65 years and above, and 65.7% agreed that vaccination can help reduce medical costs during Hajj and Umrah seasons. Additionally, 61.1% of CPs recommended updating immunization against vaccine-preventable diseases for all travelers to ensure a safe Hajj and Umrah. The overall mean knowledge of CPs regarding vaccination during Hajj and Umrah was 4.739(2.49) (median = 5; Range = 0-9). However, 56.7% of CPs demonstrated good knowledge, while 43.3% reported poor knowledge regarding vaccination during Hajj and Umrah.

Conclusion

The community pharmacists (CPs) in the Mecca region were found to have good knowledge, with more than half of them having positive attitudes about vaccination for Hajj and Umrah-related health conditions. It is crucial to enhance the knowledge and attitudes of CPs to provide better care and participate in reliable and supportive healthcare and counseling sessions for managing various health infections.

Introduction

The Hajj and Umrah are the pillars of Islam that attract people from all around the world [1,2]. The Hajj is an annual pilgrimage that happens in the city of Makkah, Saudi Arabia. It is regarded as a religious requirement for all adult Muslims worldwide who have the physical and financial ability, and an estimated 2-3 million peoples attend each year [13]. While the Hajj can be performed in the dhul Hajj month, once a year, on the other hand, Umrah can perform at any time of the year [1,2]. The peak period for Umrah is when pilgrims travel to Mecca to undertake Umrah during Ramadan. During gatherings or crowded places, there were always higher chances of the development of various infections [4,5].

According to the literature, a diverse range of nations were represented by the majority of pilgrims, particularly those performing Hajj, such as Indonesia, Pakistan, India, Malaysia, Nigeria, and Egypt [6]. Dengue fever, lymphatic filariasis (LF), soil-transmitted helminth diseases, and leprosy were more widespread in tropical nations in South and Southeast Asia [1,2,4,5,7]. Although previous research has shown that respiratory illnesses are the most common among pilgrims [4,5] with a prevalence of up to 90% [8]. Another recent comprehensive analysis, on the other hand, revealed a rhinovirus prevalence of 5.9-48.8%, followed by influenza virus at 13.9% and non-Middle East Respiratory Syndrome coronavirus at (MERS) coronaviruses at 13.2% [9] Similarly, Salmon-Rousseau et al [4,5] reported respiratory tract infections, ENT infections, pyogenic pneumonia, whooping cough, TB, and meningococcal meningitis. Among pilgrims, additional waterborne diseases like gastroenteritis and hepatitis A were widespread [4,5].

It was evidenced that respiratory infections are the most common infections in the holy cities and the majority of visitors who come from different nations to perform their rituals develop at least one form of respiratory infection or another during their stay in holy cities including Madina [912]. The incidence of illnesses during the mass gatherings can be attributed to several factors, including overcrowding, changes in climatic conditions, pollution, and shared accommodation. Additionally, it is worth considering that many pilgrims may be elderly individuals aged 50 years or older with chronic diseases and comorbidities, such as hypertension and diabetes [13,14].

Pharmacists, as front-line health care professionals must recognize possible infections, during the Hajj and Umrah to reduce the risk of health-related complications, which can result in chronic conditions, comorbidities, increased costs to the patients and may lead to endemics or pandemics, if not treated or recognized promptly [1518]. As a result, health care providers in all practice settings must be vigilant in checking for potential risks of infections and diseases and, prescribe medications for the patients to control the infectious diseases as well as patient counseling on foods and other beverages [1618]. For example, investigations have discovered that mass gathering is more likely to cause various infections including food, allergic reactions, flu, and cough [10,13,19,20]. Furthermore, multinational pilgrims when combined, the possibilities of infections can be further higher, which may increase the risk of unwanted consequences [19,20].

Pharmacists play an important role in the individual’s, health and management from whom people seek medical guidance [17,18]. In this view, CPs were playing a significant role in controlling various infections, therefore posing adequate knowledge helps CPs to be more vigilant about the recognition of new strains of infections at their practice site. Their expertise in dispensing medications, offering health consultations, and promoting preventive care contributes to the overall health and safety of pilgrims in the challenging and physically demanding pilgrimage environments. The accessibility and guidance provided by community pharmacists contribute significantly to the pilgrims’ ability to manage health conditions effectively, fostering a safer and more fulfilling religious experience during Hajj and Umrah.

There have been several reports published previously from around the world to study the knowledge, attitudes, and practice of pharmacists towards the prevention of infections in the Hajj and Umrah. As per our knowledge, no such research has been conducted so far among Saudi pharmacists working in the western region of Saudi Arabia. Hence, the present study was designed to investigate knowledge and attitude about Hajj and Umrah-related health conditions in the Western Region, of Saudi Arabia.

The rationale for the study stems from the significance of the annual Hajj and Umrah pilgrimages in the region and the pivotal role community pharmacists play in public health. Given the large influx of pilgrims during these religious events, there is a heightened risk of various health conditions.

Method

2.1. Study design

A cross-sectional, online survey study was conducted between 1st March to 30th April 2023 among Community pharmacists (CPs) living Makkah, Madinah, Jeddah and Taif which represent the western region of Saudi Arabia to evaluate their knowledge and attitude about Hajj and Umrah-related health conditions.

2.2. Survey respondent selection process and data collection

It is a prospective self-reporting survey using online questionnaire involving CPs who are registered with the Saudi Commission for Health Specialties (SCFHS), currently practicing in the community pharmacies, and CPs who agreed to provide informed consent were included in the study. The study excluded CPs from the other regions of Saudi Arabia and those who are not in the practice. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the research ethical committee at Umm Al-Qura University, Makkah, Saudi Arabia (approval number. HAPO-02-K-012-2022-11-1314). Before data collection the CPs were informed about the objectives of the study and verbal informed consent was obtained from all respondents emphasizing the confidentiality and use of personal data for the research work only. Furthermore, participation in this study was voluntary, no monetary or non-monetary rewards were provided, and participants were free to leave at any time.

2.3. Sample size estimation

A simple sampling method was utilized, and the required sample size was calculated using an online sample size calculator (https://www.openepi.com/SampleSize/SSCohort.htm), with a 95% confidence level and 5% margin of error. Since the outcomes for each question were unknown, a response distribution of 50% was assumed [21]. Based on this calculation, the sample size was determined to be 384 subjects. However, to enhance the data’s reliability, we aimed to survey around 500 pharmacists.

2.4. Questionnaire design

The questionnaire employed in this study was formulated by conducting a thorough review of the available literature on health-related conditions during Hajj and Umrah, as well as the official websites of the Saudi Ministry of Health [19,20]. The questionnaire for this study was structured into four distinct sections, encompassing a total of 32 questions. The first section consisted of nine questions aimed at gathering demographic information about the participants, such as age, gender, education level, year of experience, country of qualifications, and pharmacy location. Additionally, this section inquired about the advice, services, and time devoted to Hajj and Umrah health-related conditions. The second section comprised 16 questions designed to measure the participants’ knowledge of Hajj and Umrah health-related conditions. The questions were presented in multiple-choice format, with some questions using a 3-point scale (Yes/No/I don’t know) to elicit responses. The third section collected information on the attitudes of CPs towards vaccination and related health conditions among pilgrims. Participants were asked to respond on a 3-point scale (Yes/No/I don’t know) regarding which conditions to seek health behavior for. Lastly, the fourth section focused on the medication used to manage influenza and other related conditions.

The questionnaire developed for this study underwent a two-step validation process. First, the initial draft was reviewed by a group of research experts, and secondly, a pilot study was conducted among a small sample of 15 individuals to ensure readability and ease of administration. Feedback from the pilot study was incorporated into the final questionnaire, which had a reliability coefficient of knowledge items 0.85, attitudes 0.72 and awareness 0.74 as measured by Cronbach’s Alpha, indicating its suitability for the study. The final version was distributed to CPs in the selected locations using an online survey tool, with one reminder sent to encourage participation. The pilot study data was not included in the final analysis.

To assess the knowledge of CPs about vaccination, a total of 10 knowledge items were used. A score of ‘one’ was given for each correct answer, and a score of ‘zero’ for each incorrect answer. The overall knowledge score was determined by adding up the scores for all 10 items. The knowledge score was then categorized as ‘Good’ for scores greater than 50% of the total knowledge score, and ‘Poor’ for scores less than 50% of the total knowledge score[22,23].

2.5. Statistical analysis

The collected data was analyzed using Statistical Package for Social Sciences version 26.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics such as frequencies (n) and percentages (%) were computed. The knowledge scores were tabulated for the knowledge items. To investigate the relationship between the demographic characteristics of the CPs and their knowledge, the multiple linear regression was employed. A significance level of p < 0.05 was set to determine statistical significance.

Results

The survey was completed by a total of 496 CPs by giving a response rate of 99.2% (n = 500). The majority of the respondents (71.8%) were male, while 28.2% were female. Among the CPs, approximately 37% (n = 182) were aged between 31 and 35, and 27.2% were aged between 26 and 30. In terms of experience, 35.1% had 6-10 years of experience, and 28.8% had 11-15 years of experience. A majority of the CPs (55.4%) held a bachelor’s degree in pharmacy, while 27.2% held a PharmD degree. Regarding their country of qualification, 45% of the CPs were qualified in Egypt, 18.5% in Saudi Arabia, and 13.5% in Yemen. More than half of the respondents (53.2%) were urban dwellers. Table 1 provides detailed information about the demographic characteristics of the CPs.

Table 1. Demographic characters of the community pharmacist (n = 496).

Variables Frequencies (n) Percentage (%)
Gender
Male 356 71.8%
Female 140 28.2%
Age(Years)
21-25 32 6.5%
26-30 135 27.2%
31-35 182 36.7%
36-40 95 19.2
>41 52 10.5%
Years of experience
0-5 years 103 20.8%
6-10 years 174 35.1%
11-15 years 143 28.8%
>15 years 76 15.3%
Educational level
Diploma in pharmacy\Technician 34 6.9%
Bachelor\Bpharm 275 55.4%
PharmD (Doctor of Pharmacy) 135 27.2%
Postgraduate 52 10.5%
Country of qualification
Saudi Arabia 92 18.5%
Egypt 223 45%
Yemen 68 13.7%
Pakistan 58 11.7%
India 32 6.5%
Other countries 23 4.6%
Pharmacy location
Rural 232 46.8%
Urban 264 53.2%

The results of the study indicate that a majority of CPs, 55.1%, had knowledge of the required vaccines for Hajj and Umrah. When it came to providing advice or services related to Hajj and Umrah health-related diseases, 46.6% of CPs reported offering health advice to pilgrims while 32.1% did not. Interestingly, 46.6% of CPs also reported receiving or seeing a pilgrim at the pharmacy complaining of infection. A small proportion of CPs, 14.5%, reported spending more than 1 hour per day offering Hajj and Umrah health-related advice to pilgrims, while 14.3% reported spending less than 1 hour per day. More detailed responses regarding the characteristics of the services provided by CPs can be found in Table 2.

Table 2. CPs’ responses towards awareness of the required vaccines for Hajj and Umrah and providing health-related advice to the pilgrims.

Variables Frequency (n) Percentage (%)
Do you aware of the required vaccines for Hajj and Umrah Health
Yes 212 55.1%
No 75 19.5%
I don’t know 98 25.5%
Do you provide Hajj and Umrah health-related conditions advice or services to the patients?
Yes 231 46.6%
No 159 32.1%
I don’t know 106 21.4%
Have You Seen or received a pilgrim to the pharmacy about Complaining of infection/ problem?
Yes 231 46.6%
No 198 39.9%
How much time or days do you spend on providing Hajj and Umrah health-related conditions advice to pilgrims?
Less than 1 hour per day 71 14.3%
More than 1 hour per day 72 14.5%
Less than 1 hour per week 78 15.7%
More than 1 hour per week 50 10.1%
Everyday 95 19.2%
Less than 1 hour in a month 53 10.7%

The results of this study showed that diarrhea (59.5%, n = 234) was the most common health condition reported during Hajj and Umrah seasons, followed by flu and cough (58%, n = 228), gastrointestinal diseases (39.4%, n = 155), food poisoning (33.6%, n = 132), and viral fever and heat stroke (24.4% and 24.4%, respectively; n = 96 each). A breakdown of the responses provided by CPs regarding the most prevalent infectious diseases during these seasons can be found in Fig 1.

Fig 1. CPs responses towards the most common Hajj and Umrah health-related infectious diseases.

Fig 1

Table 3 outlines the extent of knowledge among CPs regarding diarrhea and its management. The results indicated that a significant proportion of CPs (n = 143, 37.8%) identified Enter Toxigenic E. coli as the most common causative agent of diarrhea, followed by Salmonella (21.2%, n = 80) and Rotaviruses (16.9%, n = 64) (as presented in Table 2). In terms of managing diarrhea, 48.3% of CPs (n = 185) believed that no active treatment is necessary, and only maintaining hydration using Gastrolyte® and allowing diarrhea to resolve naturally. In contrast, 27.7% of CPs (n = 106) suggested starting treatment immediately with loperamide while consuming plenty of fluids. A smaller proportion of CPs (n = 21, 5.5%) recommended one dose of doxycycline 200 mg in addition to loperamide and fluid intake to treat diarrhea. Further details of the CPs’ responses are provided in Table 3.

Table 3. Knowledge of CPs towards diarrhea and its management.

Characters Frequency
(n)
Percentage (%)
The most common causative organism for diarrhea during Hajj and Umrah
Enter toxigenic E. coli (ETEC) 143 37.8%
Giardia intestinalis 57 15.1%
Salmonella 80 21.2%
Rotaviruses 64 16.9%
Campylobacter pylori 34 9%
The preferred method for treatment option of diarrhea during Hajj and Umrah
No active treatment, just maintain hydration using Gastrolyte ® and allow the diarrhea to take its course. 185 48.3%
Start treatment immediately with loperamide whilst drinking plenty of fluids. 106 27.7%
Start treatment immediately with one dose of norfloxacin 800 mg plus loperamide whilst drinking plenty of fluids. 44 11.55%
Start treatment immediately with one dose of norfloxacin 800 mg whilst drinking plenty of fluids. 27 7%
Start treatment immediately with one dose of doxycycline 200 mg plus loperamide whilst drinking plenty of fluids 21 5.5%

3.1. Community pharmacist responses towards First aid items recommendations to pilgrims

The responses of CPs regarding the most recommended first aid items for pilgrims were analyzed. More than half of the CPs (53.6%; n = 266) suggested oral rehydration sachets, followed by face masks recommended by 39.7% of the CPs (n = 197), and painkillers or paracetamol tablets by 38.7% of the CPs (n = 192). Additionally, 37.95% of the CPs recommended using sunscreen or hats to protect against the sun, while 35.3% suggested carrying a small range of bandages or dressings (n = 175). The detailed responses of the CPs regarding the recommended first aid kits for pilgrims were provided in Fig 2.

Fig 2. CPs responses towards first aid items recommendations to pilgrims.

Fig 2

In addition, a considerable proportion of CPs (38.5%; n = 191) believed that influenza vaccination would be administered to pilgrims before their departure to Saudi Arabia. This was followed by Meningococcal Meningitis at 14.1% (n = 70), polio at 11.1% (n = 55), Hepatitis A at 8.9% (n = 44), Tetanus at 8.3% (n = 41), and Measles at 7.5% (n = 37). For a comprehensive overview of the CPs’ responses on the most commonly known vaccines given before traveling to Saudi Arabia, refer to Fig 3.

Fig 3. CPs responses towards the most common vaccines, given before traveling to Saudi Arabia.

Fig 3

Despite the fact that 57.1% of the CPs acknowledged the necessity of vaccination to safeguard and impede the spread of infectious diseases before visiting Saudi Arabia, 64.8% of them claimed that flu was prevalent among Hajj and Umrah travelers. The comprehensive replies of the CPs regarding vaccination practices during Hajj and Umrah were outlined in Table 4.

Table 4. Knowledge of CPs about the vaccination during Hajj and Umrah.

Questionnaires Frequency
(n)
Percentages
(%)
The vaccine is recommended for the protection and to prevent the spread of infectious diseases before traveling to Saudi Arabia
Yes 283 57.1%
No 108 21.8%
I don’t know 105 21.2%
Influenza is common among Hajj and Umrah travelers
Yes 250 64.8%
No 57 14.8%
I don’t know 79 20.5%
Younger adults have a higher risk of complications from influenza and other Hajj and Umrah health-related conditions.
Yes 133 34.8%
No 165 43.2%
I don’t know 84 22%
Influenza may be transmitted from person to person easily during Haj and Umrah
Yes 253 65.9%
No 49 12.8%
I don’t know 82 21.4%
The vaccine protects against influenza infections and is not obligatory to obtain Haj or Umrah visas.
Yes 148 38.4%
No 129 33.5%
I don’t know 108 28.1%
Visitors arriving for Umrah or pilgrimage (Hajj) or seasonal work are required to submit a certificate of vaccination with the quadrivalent (ACYW135) vaccine against meningitis issued no more than 3 years and no less than 10 days before arrival in Saudi Arabia
Yes 177 46.1%
No 80 20.8%
I don’t know 127 33.1%
The pathogen that causes influenza is divided into three types: A, B, and C
Yes 179 47.1%
No 89 23.4%
I don’t know 112 29.5%
A respiratory disease that attacks the upper and/or lower respiratory tracts was more common among Hajj and Umrah pilgrims
Yes 299 60.3%
No 106 21.4%
I don’t know 91 18.3%
Mortality due to influenza globally is low
Yes 129 33.7%
No 145 37.9%
I don’t know 109 28.5%
Children, adults, and the elderly have the same risk of infection during the Hajj and Umrah seasons
Yes 188 37.9%
No 223 45%
I don’t know 85 17.15
Mean(Std) 4.739 (std = 2.49)
Median 5.00
Range 0-9

In relation to attitudes towards vaccination, the study found that 55.3% (n = 218) of CPs agreed that vaccination is a safe option for pilgrims aged 65 years and above, while 65.7% (n = 257) agreed that vaccination can help in reducing medical costs during the Hajj and Umrah seasons. Moreover, 61.1% (n = 303) of CPs recommended updating immunization against vaccine-preventable diseases for all travelers to ensure a safe pilgrimage. The detailed responses of CPs regarding their attitudes towards vaccination are presented in Table 5. The study also found that the majority of CPs (69.4%) reported prescribing analgesics, followed by facemasks (55.6%), lozenges (55%), hand hygiene products (54.2%), oral rehydration salts (51.8%), antimalarial drugs (23.8%), and antibiotics (21.6%) for Hajj and Umrah pilgrims. The detailed prescribing pattern by CPs during Hajj and Umrah is shown in Fig 4.

Table 5. Attitude of CPs regarding vaccination and other related conditions among pilgrims.

Variables Frequencies
(n)
Percentages
(%)
Vaccination is safe to be given to Hajj and Umrah perfumers aged ≥  65 years.
Yes 218 55.3%
No 99 25.1%
I don’t know 77 19.5%
Vaccination can save medical costs during the Hajj and Umrah seasons.
Yes 257 65.7%
No 58 14.8%
I don’t know 76 19.4%
Updating immunization against vaccine-preventable diseases in all travelers is strongly recommended for safe haj and Umrah.
Yes 303 61.1%
No 107 21.6%
I don’t know 86 17.3%
Influenza vaccination for Haj and Umrah performers should be done twice a year.
Yes 240 48.4%
No 148 29.8%
I don’t know 108 21.8%

Fig 4. Commonly prescribed medication for Haj and Umrah-related health conditions.

Fig 4

Despite the mean knowledge score of 4.739(2.49) (median = 5; Range = 0-9) among CPs in this study regarding vaccination during Hajj and Umrah, the findings revealed that 56.7% of the CPs exhibited good knowledge, whereas 43.3% demonstrated poor knowledge of the subject as shown in Fig 5.

Fig 5. Knowledge levels of CPs regarding the vaccination.

Fig 5

To determine the relationship between knowledge of vaccination, with community pharmacist age, gender, education level, years of experience, country of qualification, pharmacy location and Umrah related information, a multiple regression linear model was utilized in which age, gender, education level, years of experience, country of qualification, pharmacy location and Umrah related information were considered as explanatory variables and knowledge of vaccination as the dependent variable. However, there was no association between the knowledge of vaccination and the education levels of the community pharmacist, and the amount of time spent on providing Umrah related health advice, as shown in Table 6. All other variables were significantly associated with the knowledge of vaccination as shown in Table 6.

Table 6. Results of knowledge of vaccination with Demographic characters of the community pharmacist using regression analysis.

Variables Unstandardized Coefficients Standardized Coefficients t Sig. 95.0% Confidence Interval for B
B Std. Error Beta Lower Bound Upper Bound
(Constant) 2.500 .189 13.197 .000 2.127 2.872
Gender -.230 .056 -.194 -4.084 .000 -.340 -.119
Age (Years) .053 .027 .112 2.000 .046 .001 .106
Educational level -.056 .031 -.082 -1.793 .074 -.117 .005
Years of experience in community pharmacy -.057 .028 -.115 -2.070 .039 -.112 -.003
Country of qualification -.058 .019 -.145 -3.035 .003 -.095 -.020
Pharmacy Location .093 .045 .092 2.071 .039 .005 .181
Do you provide Hajj and Umrah health-related conditions advice or services to the patients? -.204 .030 -.323 -6.731 .000 -.264 -.144
Have You Seen or received a pilgrim to the pharmacy about Complaining of infection/ problem? -.137 .045 -.141 -3.048 .002 -.226 -.049
How much time or days you spend on providing Hajj and Umrah health-related conditions advice pilgrims. .013 .011 .053 1.112 .267 -.010 .035

Discussion

To the best of our knowledge, no previous research has examined the knowledge and attitudes of CPs regarding Hajj and Umrah infections in the western region of Saudi Arabia. There is limited literature available on the topic of knowledge and attitudes towards Hajj and Umrah infections, both domestically and globally. However, most of the literature has concentrated on medication use during Hajj while neglecting the subject of diseases [1,4,9]. This study has the potential to make a significant scientific contribution towards enhancing public health for individuals who travel from various countries to perform religious rituals at holy sites. By providing appropriate awareness and counseling from CPs, this study can serve as a valuable reference for future national and international research. Moreover, the findings can aid educational and hospital institutions in establishing appropriate continuing education efforts for practicing pharmacists to enhance their knowledge and attentiveness, especially for those working in holy cities.

According to the results of this survey, the most suggested medication for pilgrims was oral rehydration sachets (53.6%; n = 266). The next most frequently recommended items were face masks (39.7%; n = 197) and painkillers/paracetamol tablets. Approximately 39% of the CPs recommended the use of sunscreen or hats, while a limited range of bandages or dressings were suggested by 35.3% of the CPs. These findings were like those of Yezli et al. in 2020, Shakir et al. in 2006, and Stagelund et al. in 2019 [19,20,24,25]. For instance, a previous study by Yezli et al in 2020 among pilgrims visiting outpatients during the Hajj gathering reported the use of nonsteroidal anti-inflammatory drugs, paracetamol (16.61%), antihistamines (2.19%), oral rehydration salts (1.24%) and antipyretics, and antibacterial medicines [19]. Furthermore, pilgrims were prescribed an average of 2.6 medications on each consultation and polypharmacy was reported in 4.8% of the encounters [19]. Antibiotics and injections were prescribed in 46.9% and 6.5% of encounters, respectively [19]. Similarly, Shakir et al., 2006, and Stagelund et al.2019 reported that paracetamol, antibacterial, drugs acting GIT, and antihistamines were the most common drugs prescribed to pilgrims[24,25]. On the other hand, another recent study by Yezli et al in 2021 aimed to assess the Medication Handling and Storage among pilgrims during the Hajj Mass Gathering, reported that 44.4% of the pilgrims used medication and 60.2% of the pilgrims purchased from Saudi Arabia [26]. In addition, 36.6% of the medicines were prescribed by pharmacists and 78.8% of them were prescribed by physicians.

Furthermore 91.6% of the pilgrims used 1-4 medications [26]. Another study among pilgrims or visitors to Mecca reported having painkillers for Anti-diarrhea, Anti-constipation, and Antibiotic medications [27]. This indicates the seriousness of the various outbreaks caused by Bactria, viruses, and parasites, which may be the result of non-compliance with health guidelines among visitors and pilgrims [28].

However, a recent report from local news in Saudi Arabia also revealed that despite having correct vaccinations, visitors and Pilgrims who are coming to the country for Umrah or Hajj are encouraged to bring health kits as a precaution against Swine Flu [2931]. This report on the other hand confirmed the possibility of getting various infection [29,31]. Therefore, it is advisable that visitors and pilgrims must take care of their health through adequate precautionary measures particularly for the prevention of droplet infections, by using facemasks and hand sanitizers [3032].

According to the findings of this study, the most common illness reported during the Hajj and Umrah was diarrhea (59.5%), followed by flu and cough (58%), gastrointestinal illnesses (39.4%), food poisoning (33.6%), viral fever (24.4%), and heat stroke (24.4%). These findings were consistent with a recent study published in 2019 by Yezli et al, who showed that 9.7% of pilgrims experienced GI symptoms, while 5.1% (69/1363) of pilgrims experienced diarrhea [27]. Many other studies reported upper respiratory viral infections and bacterial respiratory infections [33]. These findings demonstrated the acquirement of enteric pathogens and parasites at mass gatherings, which may be contributing the infectious diseases [34,35]. Although it is well documented that despite the precautionary behavior and adequate sanitizing techniques followed by the pilgrims, still stomach disorders, poisoning outbreaks, and diarrhea continue to occur in the holy cities, during the mass gathering [35,36].

Even though the overall mean knowledge of CPs about vaccination during Hajj and Umrah in this study was 4.739(2.49) (median = 5; Range = 0-9). However, the study found that 56.7% of the CPs had good knowledge, while 43.3% had poor knowledge of vaccination during Hajj and Umrah. The greatest knowledge score was reported on how common influenza illness is during Umrah and Hajj (64.8%), followed by person-to-person transmission being the main mode of transmission during Haj and Umrah (65.9%). Although the knowledge of levels may differ from one study to another which may be influenced by several factors including the study method, respondents, and demographics of the subjects, it is evidenced that practicing pharmacists would be found to have good knowledge and then student pharmacists. In addition, various educational interventions should be recommended for the practicing pharmacist to get up-to-date information on the prevention and management of various infectious diseases, which may help in controlling and adequate management of the diseases among pilgrims and patients.

Vaccinations were given to international pilgrims to prevent influenza and other diseases [33]. Influenza is seen as a disease that may be avoided with effective vaccination, hence it is recommended for all individuals above the age of six months [35,37]. Elderly individuals, as well as those with chronic medical conditions, were more likely to develop a serious case of influenza. Individuals with chronic disease conditions and the elderly should get the seasonal influenza vaccine each year before traveling [2,35]. Our findings revealed that although the majority of CPs were aware of the essential vaccines for Hajj and Umrah before coming to Saudi Arabia, CPs’ knowledge of various illnesses and vaccinations might be improved. As of now, no study has been published to assess CPs’ knowledge, and attitudes toward various infections, management, and vaccination during Haj and Umrah, thus, we cannot make a direct comparison with other studies however, a previous study among health care professionals in Saudi Arabia reveals a positive attitude toward vaccination, as the majority believes vaccination is effective in preventing and shortening the duration of infection and remission [38].

The current study has some limitations that should be taken into account. Firstly, the research was confined to only one region in the western province of Saudi Arabia. Therefore, the generalizability of these findings to other regions may be limited. Additionally, the use of self-reported questionnaires may introduce social desirability bias in the responses provided, therefore future studies with other data collection methods are required to provide more accurate responses. Despite these limitations, the study has several strengths. Firstly, it highlights the crucial role of CPs in providing adequate treatment and management for various illnesses during mass gatherings in holy cities. Furthermore, there is a lack of research focusing on CPs and their involvement in vaccinations and infectious diseases in Saudi Arabia. By focusing on CPs, this study provides valuable insights into how their knowledge could improve health outcomes for pilgrims and facilitate better treatment. Finally, future research should aim to conduct comprehensive surveys that allow pharmacists from all regions of Saudi Arabia with varying levels of experience to participate.

Conclusion

In summary, community pharmacists (CPs) in the Mecca region were found to have good knowledge, with more than half of them having positive attitudes about vaccination for Hajj and Umrah-related health conditions. Most CPs agreed that a vaccine is recommended before traveling to Saudi Arabia for protection and to prevent the spread of infectious diseases. The most common infectious diseases in the holy cities were diarrhea, followed by flu, cough, gastrointestinal illnesses, food poisoning, viral fever, and heat stroke. Furthermore, CPs’ attitudes toward vaccination need to be improved. There is a need to encourage pharmacists to engage in planned and focused ongoing education programs on the management of various diseases at holy cities during mass gatherings. Additionally, it is recommended that individuals and visitors be more vigilant towards the possibility of infections through awareness and education about safety and precautionary measures with the help of healthcare providers such as pharmacists or physicians to protect against the various infectious diseases that may be present during mass gatherings.

Supporting information

S1 File. Hajj & Umrah.

(XLSX)

pone.0317000.s001.xlsx (69KB, xlsx)

Abbreviation:

CPs

Community pharmacists

LF

Lymphatic filariasis (LF)

MERS

Middle East Respiratory Syndrome

SCFHS

Saudi Commission for Health Specialties

SPSS

Statistical Package for the Social Sciences.

Data Availability

The relevant data can be accessed with the following DOI: (https://doi.org/10.6084/m9.figshare.28357232).

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Almutairi MM, Alsalem WS, Hassanain M, Hotez PJ. Hajj, Umrah, and the neglected tropical diseases. PLoS Negl Trop Dis. 2018;12(8):e0006539. doi: 10.1371/journal.pntd.0006539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Al-Tawfiq JA, Gautret P, Memish ZA. Expected immunizations and health protection for Hajj and Umrah 2018 -An overview. Travel Med Infect Dis. 2017;19:2–7. doi: 10.1016/j.tmaid.2017.10.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Shafi S, Booy R, Haworth E, Rashid H, Memish ZA. Hajj: health lessons for mass gatherings. J Infect Public Health. 2008;1(1):27–32. doi: 10.1016/j.jiph.2008.08.008 [DOI] [PubMed] [Google Scholar]
  • 4.Salmon-Rousseau A, Piednoir E, Cattoir V, de La Blanchardière A. Hajj-associated infections. Med Mal Infect. 2016;46(7):346–54. doi: 10.1016/j.medmal.2016.04.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Memish ZA, Steffen R, White P, Dar O, Azhar EI, Sharma A, et al. Mass gatherings medicine: public health issues arising from mass gathering religious and sporting events. Lancet. 2019;393(10185):2073–84. doi: 10.1016/S0140-6736(19)30501-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Asian countries top list of pilgrims to Makkah. 2019. Available from: https://www.arabnews.com/node/1605131/saudi-arabia [Google Scholar]
  • 7.Herricks J, et al. Studie globálního zatížení nemocemi 2013: co to znamená pro NTD. PloS Negl Trop Dis. 2017;11(1):e0005424. doi: 10.1371/journal.pntd.0005424 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hoang V-T, Dao T-L, Ly TDA, Belhouchat K, Chaht KL, Gaudart J, et al. The dynamics and interactions of respiratory pathogen carriage among French pilgrims during the 2018 Hajj. Emerg Microbes Infect. 2019;8(1):1701–10. doi: 10.1080/22221751.2019.1693247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gautret P, Benkouiten S, Al-Tawfiq JA, Memish ZA. Hajj-associated viral respiratory infections: A systematic review. Travel Med Infect Dis. 2016;14(2):92–109. doi: 10.1016/j.tmaid.2015.12.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Al-Tawfiq JA, Zumla A, Memish ZA. Respiratory tract infections during the annual Hajj: potential risks and mitigation strategies. Curr Opin Pulm Med. 2013;19(3):192–7. doi: 10.1097/MCP.0b013e32835f1ae8 [DOI] [PubMed] [Google Scholar]
  • 11.Rashid H, Shafi S, Booy R, El Bashir H, Ali K, Zambon M, et al. Influenza and respiratory syncytial virus infections in British Hajj pilgrims. Emerg Health Threats J. 2008;1:e2. doi: 10.3134/ehtj.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Awwad FA, Mohamoud MA, Abonazel MR. Estimating COVID-19 cases in Makkah region of Saudi Arabia: Space-time ARIMA modeling. PLoS One. 2021;16(4):e0250149. doi: 10.1371/journal.pone.0250149 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Dauda Goni M, Hasan H, Naing NN, Wan-Arfah N, Zeiny Deris Z, Nor Arifin W, et al. Assessment of Knowledge, Attitude and Practice towards Prevention of Respiratory Tract Infections among Hajj and Umrah Pilgrims from Malaysia in 2018. Int J Environ Res Public Health. 2019;16(22):4569. doi: 10.3390/ijerph16224569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Madani TA, Ghabrah TM, Al-Hedaithy MA, Alhazmi MA, Alazraqi TA, Albarrak AM, et al. Causes of hospitalization of pilgrims in the Hajj season of the Islamic year 1423 (2003). Ann Saudi Med. 2006;26(5):346–51. doi: 10.5144/0256-4947.2006.346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alomi YA, Abdullah Hakami LE, Yahya Khayat NA, Bamagaus YA, Rafuden Bakhsh TM, Adnan Khayat N, et al. Mass Gathering (Hajj) Pharmacy Infection Control: New Initiative in Saudi Arabia. IJPCS. 2020;9(1):5–9. doi: 10.5530/ijpcs.2020.9.2 [DOI] [Google Scholar]
  • 16.Durand C, Douriez E, Chappuis A, Poulain F, Yazdanpanah Y, Lariven S, et al. Contributions and challenges of community pharmacists during the COVID-19 pandemic: a qualitative study. J Pharm Policy Pract. 2022;15(1):43. doi: 10.1186/s40545-022-00438-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Syed Snr W, Bashatah A, A Al-Rawi MB. Evaluation of Knowledge of Food-Drug and Alcohol-Drug Interactions Among Undergraduate Students at King Saud University - An Observational Study. J Multidiscip Healthc. 2022;15:2623–33. doi: 10.2147/JMDH.S391363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Syed W, Samarkandi OA, Alsadoun A, Al Harbi MK, Al-Rawi MBA. Evaluation of clinical knowledge and perceptions about the development of thyroid cancer—an observational study of healthcare undergraduates in Saudi Arabia. Frontiers in Public Health. 2022;10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yezli S, Zaraa S, Yassin Y, Mushi A, Stergachis A, Khan A. Medication utilization pattern among outpatients during the Hajj mass gathering. Saudi Pharm J. 2020;28(9):1122–8. doi: 10.1016/j.jsps.2020.07.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Khan ID, Khan SA, Asima B, Hussaini SB, Zakiuddin M, Faisal FA. Morbidity and mortality amongst Indian Hajj pilgrims: A 3-year experience of Indian Hajj medical mission in mass-gathering medicine. J Infect Public Health. 2018;11(2):165–70. doi: 10.1016/j.jiph.2017.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ali MD, Al Hatef EAJ. Types of sampling and sample size determination in health and social science research. Journal of Young Pharmacists. 2024;16(2):204–15. [Google Scholar]
  • 22.Syed W, Al-Rawi MBA, Bashatah A. Knowledge of and attitudes toward clinical trials: A questionnaire-based study of 179 male third- and fourth-year PharmD undergraduates from Riyadh, Saudi Arabia. Med Sci Monit. 2024;30:e943468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Syed W, AlHarbi AA, Samarkandi OA, Alobaid AM, Alsulaihim IN. Navigating the Knowledge of Risk Factors, Warning Signs, of Stroke - A Community-Based Cross-Sectional Study Among Saudi Adults in Riyadh Saudi Arabia. Int J Gen Med. 2023;16:5869–83. doi: 10.2147/IJGM.S437941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Shakir HA, et al. Outpatient services during (1423h) Hajj season. Sultan Qaboos University Medical Journal. 2006;6(1):47–50. [PMC free article] [PubMed] [Google Scholar]
  • 25.Stagelund S, Andersen KG, Søe J, Roslind M, Wildgaard K. Use of Medication at the Roskilde (Denmark) Music Festival 2015 - A Prospective Observational Study of 15,133 Treated Attendees. Prehosp Disaster Med. 2019;34(4):407–14. doi: 10.1017/S1049023X19004606 [DOI] [PubMed] [Google Scholar]
  • 26.Yezli S, Yassin Y, Mushi A, Balkhi B, Stergachis A, Khan A, et al. Medication handling and storage among pilgrims during the Hajj mass gathering. Healthcare. 2021. MDPI. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yezli S, Yassin Y, Mushi A, Aburas A, Alabdullatif L, Alburayh M, et al. Gastrointestinal symptoms and knowledge and practice of pilgrims regarding food and water safety during the 2019 Hajj mass gathering. BMC Public Health. 2021;21(1):1288. doi: 10.1186/s12889-021-11381-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gautret P, Steffen R. Communicable diseases as health risks at mass gatherings other than Hajj: what is the evidence? Int J Infect Dis. 2016;4746–52. doi: 10.1016/j.ijid.2016.03.007 [DOI] [PubMed] [Google Scholar]
  • 29.MoH, T.S.A.M.o.H. Health requirements and recommendations for Hajj and Umrah performers and those working in Hajj area. English. 2015. [Google Scholar]
  • 30.Al Ruwaithi AA. The emergency medical services delivery in mass gathering events: a case study of the Hajj. University of Delaware; 2021. [Google Scholar]
  • 31.Rasooldeen M. Pilgrims urged to carry health kits as precaution against swine flu. Riyadh, Saudi Arabia: Arab News; 2009. [Google Scholar]
  • 32.Razavi SM, Mardani M, Salamati P. Infectious Diseases and Preventive Measures During Hajj Mass Gatherings: A Review of the Literature. Arch Clin Infect Dis. 2018;13(3). doi: 10.5812/archcid.62526 [DOI] [Google Scholar]
  • 33.Alfelali M, Barasheed O, Koul P, Badahdah A-M, Bokhary H, Tashani M, et al. Influenza vaccine effectiveness among Hajj pilgrims: a test-negative case-control analysis of data from different Hajj years. Expert Rev Vaccines. 2019;18(10):1103–14. doi: 10.1080/14760584.2019.1646130 [DOI] [PubMed] [Google Scholar]
  • 34.Al-Tawfiq JA, Gautret P, Benkouiten S, Memish ZA. Mass Gatherings and the Spread of Respiratory Infections. Lessons from the Hajj. Ann Am Thorac Soc. 2016;13(6):759–65. doi: 10.1513/AnnalsATS.201511-772FR [DOI] [PubMed] [Google Scholar]
  • 35.Hamid SM, Siddiqui MI, Akhtar S, Raef QM, Khalid M, Khan F, et al. Efficacy of flu vaccine among Hajj pilgrims. Pakistan Journal of Chest Medicine. 2015;21(3):96–9. [Google Scholar]
  • 36.Hoang V-T, Dao T-L, Ly TDA, Sow D, Belhouchat K, Larbi Chaht K, et al. Gastrointestinal symptoms and the acquisition of enteric pathogens in Hajj pilgrims: a 3-year prospective cohort study. Eur J Clin Microbiol Infect Dis. 2021;40(2):315–23. doi: 10.1007/s10096-020-04018-z [DOI] [PubMed] [Google Scholar]
  • 37.Gautret P, Benkouiten S, Sridhar S, Al-Tawfiq JA, Memish ZA. Diarrhea at the Hajj and Umrah. Travel medicine and infectious disease. 2015;13(2):159-166. [DOI] [PubMed] [Google Scholar]
  • 38.Alshammari TM, Yusuff KB, Aziz MM, Subaie GM. Healthcare professionals’ knowledge, attitude and acceptance of influenza vaccination in Saudi Arabia: a multicenter cross-sectional study. BMC Health Serv Res. 2019;19(1):229. doi: 10.1186/s12913-019-4054-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Mohamed Abonazel

12 Feb 2024

PONE-D-24-02546Evaluation of Community Pharmacists' Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional study.PLOS ONE

Dear Dr. Alorfi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 28 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Mohamed R. Abonazel, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-informationhttp://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. Author need to do statistical analyses (significance level of p<0.05)

2. How the author makes sure that the participants were not biased towards specific answer

3. How the author makes sure that the participants were not disengaged while answering.

4. How the author makes sure about reliability of result

Reviewer #2: It is an honor for me to review a manuscript number " PONE-D-24-02546 " titled " Evaluation of Community Pharmacists' Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional Study" for the " PLOS ONE’' journal. The manuscript looks interesting and significant locally however, the following major modification is required.

• The introduction is poorly described and not aligned with the study objective

• Kindly add the rationale of the study under the last paragraph of the introduction

• Kindly add how survey tools were developed

• Kindly write Cronbach’s alpha values

• Kindly add how survey respondents were selected

• How respondents were identified

• How survey link was disseminated among the respondents

• Kindly add the study site

• How study respondents were biased

• Kindly add exclusion criteria for the study

• Discussion needs to update and compare findings with the latest published article

• Please scan your manuscript again and correct some topological errors

• Please make sure your manuscript was written in line with this journal submission guideline as well as reference styles

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Mar 18;20(3):e0317000. doi: 10.1371/journal.pone.0317000.r003

Author response to Decision Letter 0


25 Mar 2024

PONE-D-24-02546

Evaluation of Community Pharmacists' Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional study.

Dear Mohamed R. Abonazel, Ph.D.

Academic Editor

PLOS ONE

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Author response: Thanks indeed.

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

Author response: Thanks indeed. We made the requested changes.

3. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

Author response: Thanks indeed for your positive feedback.

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

Author response: Thanks indeed for your positive feedback.

5. Review Comments to the Author

Reviewer #1: 1. Author need to do statistical analyses (significance level of p ;0.05)

2. How the author makes sure that the participants were not biased towards specific answer

3. How the author makes sure that the participants were not disengaged while answering.

4. How the author makes sure about reliability of result

Author response: The study implemented rigorous measures to mitigate potential predispositions. Randomized assignment was employed to distribute participants evenly across conditions, minimizing selection bias. The design of the questionnaire was carefully crafted to avoid leading or suggestive language, and a pre-testing phase was conducted to identify and rectify any potential biases from community pharmacists in western region of Saudi Arabia. Additionally, blinding techniques were incorporated to ensure both participants and experimenters remained unaware of specific conditions, reducing the risk of bias stemming from expectations. The study also prioritized diverse participant demographics to enhance external validity because mostly of the community pharmacists are non-Saudis. Lastly, the importance of informed consent and debriefing procedures was emphasized, ensuring participants were adequately informed about the study's nature and potential biases. These comprehensive strategies collectively contribute to bolstering the study's internal validity and minimizing the likelihood of participant bias towards specific answers. Significance level of p ;0.05 were applied for all.

Reviewer #2:

It is an honor for me to review a manuscript number PONE-D-24-02546; Evaluation of Community Pharmacists; Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional Study. The manuscript looks interesting and significant locally however, the following major modification is required.

The introduction is poorly described and not aligned with the study objective.

Author response: Thanks indeed. We updated the whole manuscript including the introduction.

Kindly add the rationale of the study under the last paragraph of the introduction

Author response: Thanks indeed. Done.

Kindly add how survey tools were developed

Author response: Thanks indeed. The tool was explained under ‘’ Questionnaire design’ section.

Kindly write Cronbach’s alpha values

Author response: Thanks indeed.

Kindly add how survey respondents were selected.

Author response: Thanks indeed. We have updated the whole paragraph under ‘’ 2.2 Survey respondent selection process and data collection.’’

How survey link was disseminated among the respondents

Author response: Thank you for your insightful question. The survey link was disseminated among the respondents through a google form link. Specifically, we utilized email invitations, institutional mailing lists, etc.] to reach our target audience.

Kindly add the study site

Author response: Thanks indeed. We added the study site. Community pharmacists (CPs) living Makkah, Madinah, Jeddah and Taif which represent in the western region of Saudi Arabia

How study respondents were biased

Author response: Thanks indeed. The study implemented rigorous measures to mitigate potential predispositions. Randomized assignment was employed to distribute participants evenly across conditions, minimizing selection bias. The design of the questionnaire was carefully crafted to avoid leading or suggestive language, and a pre-testing phase was conducted to identify and rectify any potential biases from community pharmacists in western region of Saudi Arabia. Additionally, blinding techniques were incorporated to ensure both participants and experimenters remained unaware of specific conditions, reducing the risk of bias stemming from expectations. The study also prioritized diverse participant demographics to enhance external validity because mostly of the community pharmacists are non-Saudis. Lastly, the importance of informed consent and debriefing procedures was emphasized, ensuring participants were adequately informed about the study's nature and potential biases. These comprehensive strategies collectively contribute to bolstering the study's internal validity and minimizing the likelihood of participant bias towards specific answers.

Kindly add exclusion criteria for the study

Author response: Thanks indeed. Done as of ‘’The study excluded CPs from the other regions of Saudi Arabia and those who are not in the practice’’.

Discussion needs to update and compare findings with the latest published article

Author response: Thank you for your constructive feedback. We appreciate your suggestion to update and compare our findings with the latest published articles. However, the limited availability of relevant literature in for Hajj and Umrah poses a challenge. We have thoroughly searched for recent publications and, while the number is limited, we have incorporated the most pertinent ones into the discussion. We hope this addresses your concern, and we appreciate your understanding of the constraints in our field.

Please scan your manuscript again and correct some topological errors.

Author response: Thanks indeed. The manuscript underwent a significant English proofreading, and you can check the tracking.

Please make sure your manuscript was written in line with this journal submission guideline as well as reference styles

Author response: Thanks indeed. Done.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Attachment

Submitted filename: Response letter.pdf

pone.0317000.s003.pdf (122.5KB, pdf)

Decision Letter 1

Mohamed Abonazel

27 May 2024

PONE-D-24-02546R1Evaluation of Community Pharmacists' Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional study.PLOS ONE

Dear Dr. Alorfi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 11 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Mohamed R. Abonazel, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments:

The authors have been given a final opportunity to modify their research according to the comments received from the reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. Mention response rate of participants.

2. How the author makes sure that the participants were not biased towards specific answer

3. How the author makes sure that the participants were not disengaged while answering.

4. How the author makes sure about reliability of result

Reviewer #2: All, Raised comments not yet rectified. I'm afraid that neither the introduction, design of the study nor the obtained results and employed analytical methods have sufficient merit to be published in the PLOS ONE Journal. There are lots of flaws in the manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Mar 18;20(3):e0317000. doi: 10.1371/journal.pone.0317000.r005

Author response to Decision Letter 1


2 Aug 2024

The first file with track changes.

Kindly open the word file to check and track.

Kindest regards, Dr. Nasser Alorfi

Attachment

Submitted filename: Response letter (2).pdf

pone.0317000.s004.pdf (136.7KB, pdf)

Decision Letter 2

Mohamed Abonazel

21 Oct 2024

PONE-D-24-02546R2Evaluation of Community Pharmacists' Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional study.PLOS ONE

Dear Dr. Alorfi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Mohamed R. Abonazel, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

One reviewer suggested adding some references; please check these references and then add only those references related to the topic of the manuscript or the statistical analysis used in the applied study.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. Result of time spend on providing Hajj and Umrah health related conditions advice pilgrims is non significant. How the author ensure the comparison of this study with another study.

2. How the author makes sure that the participants were not biased towards specific answer

3. How the author makes sure that the participants were not disengaged while answering.

4. Author need to mention response rate

Reviewer #2: All the raised comments have been rectified by the comments. However, I am still worried about sampling and sample size calculator proper citation. Kindly add a suitable reference for sampling and a sample size calculation. Rather than just link OpenEpi:Sample Size for X-Sectional,Cohort,and Clinical Trials . However, you may use this reference for sampling and a sample size calculation. Ali MD, Hatef EAJA. Types of Sampling and Sample Size Determination in Health and Social Science Research. Journal of Young Pharmacists [Internet]. 2024 Jun 6;16(2):204–15. Available from: http://dx.doi.org/10.5530/jyp.2024.16.27 and cite them properly.

Reviewer #3: 1. The "Conclusion" section needs improvement.

2. The paper contains a few grammatical errors. The authors need to review the full text carefully.

3. Recently published papers are relevant to this manuscript, so one or all of them should be cited, such as

doi: https://doi.org/10.1016/j.jth.2022.101353 - https://doi.org/10.1371/journal.pone.0250149

----------------------------------------------------------------------------------------

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Decision Letter 3

Mohamed Abonazel

20 Dec 2024

Evaluation of Community Pharmacists' Knowledge and Attitude about Hajj and Umrah-related health conditions in the Western Region, Saudi Arabia: A Cross-sectional study.

PONE-D-24-02546R3

Dear Dr. Alorfi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mohamed R. Abonazel, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #3: The authors have adequately addressed the comments, and I feel this manuscript is now acceptable for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Mohamed Abonazel

PONE-D-24-02546R3

PLOS ONE

Dear Dr. Alorfi,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Mohamed R. Abonazel

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Hajj & Umrah.

    (XLSX)

    pone.0317000.s001.xlsx (69KB, xlsx)
    Attachment

    Submitted filename: Response letter.pdf

    pone.0317000.s003.pdf (122.5KB, pdf)
    Attachment

    Submitted filename: Response letter (2).pdf

    pone.0317000.s004.pdf (136.7KB, pdf)
    Attachment

    Submitted filename: Response Letter 03.12.2024.pdf

    pone.0317000.s005.pdf (64.8KB, pdf)

    Data Availability Statement

    The relevant data can be accessed with the following DOI: (https://doi.org/10.6084/m9.figshare.28357232).


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES